Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Shares Acquired by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. raised its holdings in shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) by 7.7% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 462,867 shares of the company’s stock after purchasing an additional 33,123 shares during the quarter. Charles Schwab Investment Management Inc.’s holdings in Taysha Gene Therapies were worth $930,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Quantum Private Wealth LLC grew its position in shares of Taysha Gene Therapies by 5.1% during the third quarter. Quantum Private Wealth LLC now owns 767,616 shares of the company’s stock worth $1,543,000 after buying an additional 37,096 shares in the last quarter. Bank of New York Mellon Corp acquired a new position in Taysha Gene Therapies during the 2nd quarter worth $1,018,000. GSA Capital Partners LLP increased its position in shares of Taysha Gene Therapies by 64.7% in the 3rd quarter. GSA Capital Partners LLP now owns 233,560 shares of the company’s stock worth $469,000 after purchasing an additional 91,755 shares during the last quarter. Los Angeles Capital Management LLC acquired a new stake in shares of Taysha Gene Therapies in the 3rd quarter valued at about $416,000. Finally, Rhumbline Advisers bought a new position in shares of Taysha Gene Therapies during the second quarter worth about $413,000. 77.70% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research firms have commented on TSHA. JMP Securities reaffirmed a “market outperform” rating and set a $5.00 target price on shares of Taysha Gene Therapies in a report on Tuesday, November 12th. Chardan Capital reaffirmed a “buy” rating and issued a $7.00 price objective on shares of Taysha Gene Therapies in a report on Thursday, November 14th. Needham & Company LLC reissued a “buy” rating and set a $6.00 target price on shares of Taysha Gene Therapies in a report on Tuesday, November 12th. Canaccord Genuity Group raised their target price on shares of Taysha Gene Therapies from $6.00 to $8.00 and gave the stock a “buy” rating in a report on Friday, November 15th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $7.00 price target on shares of Taysha Gene Therapies in a research report on Tuesday, November 12th. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $6.63.

Taysha Gene Therapies Stock Performance

Shares of TSHA stock opened at $2.03 on Wednesday. Taysha Gene Therapies, Inc. has a 12-month low of $1.19 and a 12-month high of $4.32. The company has a debt-to-equity ratio of 0.48, a current ratio of 5.51 and a quick ratio of 5.51. The firm has a market capitalization of $416.03 million, a price-to-earnings ratio of 3.22 and a beta of 0.79. The business has a 50 day simple moving average of $2.15 and a 200 day simple moving average of $2.33.

Taysha Gene Therapies Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.